AI-assisted, human-published
10/16/2025 /Funding Events
Peptilogics Secures $78 Million for Phase 2/3 Study of Zaloganan in Treating Prosthetic Joint Infections
Peptilogics secures $78 million in Series B2 financing to support the Phase 2/3 pivotal trial of zaloganan, an investigational treatment for prosthetic joint infections.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com